Get started
Author

Margaret T.L. Nguyen

Observed names: Margaret Nguyen, Margaret T. Nguyen
ORCID: 0000-0003-0878-5896
Observed ORCID: 0000-0003-0878-5896
OpenAlex ID: A5044109661
Tumor-Specific Activation of an EGFR-Targeting Probody Enhances Therapeutic Index
2013 · Luc R. Desnoyers, Olga Vasiljeva, et al. · Science Translational Medicine · 295
Identification and characterization of novel TRPV4 modulators
2009 · Fabien Vincent, Alejandra Acevedo, et al. · Biochemical and Biophysical Research Communications · 252
Probody Therapeutic Design of 89Zr-CX-072 Promotes Accumulation in PD-L1–Expressing Tumors Compared to Normal Murine Lymphoid Tissue
2020 · Danique Giesen, Linda N. Broer, et al. · Clinical Cancer Research · 54
PDF
First-in-Human Study of the Biodistribution and Pharmacokinetics of 89Zr-CX-072, a Novel Immunopet Tracer Based on an Anti–PD-L1 Probody
2021 · Laura Kist de Ruijter, Jahlisa S. Hooiveld-Noeken, et al. · Clinical Cancer Research · 48
PDF
Identification of orally-bioavailable antagonists of the TRPV4 ion-channel
2015 · Zhi-Liang Wei, Margaret T. Nguyen, et al. · Bioorganic & Medicinal Chemistry Letters · 44
The tumor targeting performance of anti-CD166 Probody drug conjugate CX-2009 and its parental derivatives as monitored by 89Zr-immuno-PET in xenograft bearing mice
2020 · Marion Chomet, Maxime Schreurs, et al. · Theranostics · 40
PDF
Monitoring protease activity in biological tissues using antibody prodrugs as sensing probes
2020 · Olga Vasiljeva, Elizabeth Menendez, et al. · Scientific Reports · 37
PDF
Potent 4-amino-5-azaindole factor VIIa inhibitors
2006 · Huiyong Hu, Aleksandr Kolesnikov, et al. · Bioorganic & Medicinal Chemistry Letters · 36
Conditional PD-1/PD-L1 Probody Therapeutics Induce Comparable Antitumor Immunity but Reduced Systemic Toxicity Compared with Traditional Anti–PD-1/PD-L1 Agents
2021 · Hikmat H. Assi, Chihunt Wong, et al. · Cancer Immunology Research · 31
Novel 5-azaindole factor VIIa inhibitors
2006 · Jennifer R. Riggs, Huiyong Hu, et al. · Bioorganic & Medicinal Chemistry Letters · 29
Design and synthesis of selective keto-1,2,4-oxadiazole-based tryptase inhibitors
2006 · James T. Palmer, Robert M. Rydzewski, et al. · Bioorganic & Medicinal Chemistry Letters · 22
2-Amino-5-arylbenzoxazole derivatives as potent inhibitors of fatty acid amide hydrolase (FAAH)
2012 · M. Angels Estiarte, Russell J. Johnson, et al. · MedChemComm · 17
Expression and characterization of recombinant γ-tryptase
2006 · Jing Yuan, Jeri Beltman, et al. · Protein Expression and Purification · 13
Novel, potent, selective, and orally bioavailable human βII-tryptase inhibitors
2006 · David Sperandio, Vincent W.-F. Tai, et al. · Bioorganic & Medicinal Chemistry Letters · 11
Abstract C165: Development of a probody drug conjugate (PDC) against CD166 for the treatment of multiple cancers
2015 · Annie Yang Weaver, Shweta Singh, et al. · Molecular Cancer Therapeutics · 10
Mining biologically-active molecules for inhibitors of fatty acid amide hydrolase (FAAH): Identification of phenmedipham and amperozide as FAAH inhibitors
2009 · Fabien Vincent, Margaret T. Nguyen, et al. · Bioorganic & Medicinal Chemistry Letters · 9
Discovery of potent, non-carbonyl inhibitors of fatty acid amide hydrolase (FAAH)
2012 · Sumithra Gowlugari, Jeff DeFalco, et al. · MedChemComm · 8
Supplementary Table S1 and S2 from First-in-Human Study of the Biodistribution and Pharmacokinetics of 89Zr-CX-072, a Novel Immunopet Tracer Based on an Anti–PD-L1 Probody
2023 · Laura Kist de Ruijter, Jahlisa S. Hooiveld-Noeken, et al.
Figure S1 from First-in-Human Study of the Biodistribution and Pharmacokinetics of 89Zr-CX-072, a Novel Immunopet Tracer Based on an Anti–PD-L1 Probody
2023 · Laura Kist de Ruijter, Jahlisa S. Hooiveld-Noeken, et al.
Figure S2 from Probody Therapeutic Design of 89Zr-CX-072 Promotes Accumulation in PD-L1–Expressing Tumors Compared to Normal Murine Lymphoid Tissue
2023 · Danique Giesen, Linda N. Broer, et al.
Figure S3 from Probody Therapeutic Design of 89Zr-CX-072 Promotes Accumulation in PD-L1–Expressing Tumors Compared to Normal Murine Lymphoid Tissue
2023 · Danique Giesen, Linda N. Broer, et al.
Figure S4 from Probody Therapeutic Design of 89Zr-CX-072 Promotes Accumulation in PD-L1–Expressing Tumors Compared to Normal Murine Lymphoid Tissue
2023 · Danique Giesen, Linda N. Broer, et al.
Figure S5 from Probody Therapeutic Design of 89Zr-CX-072 Promotes Accumulation in PD-L1–Expressing Tumors Compared to Normal Murine Lymphoid Tissue
2023 · Danique Giesen, Linda N. Broer, et al.
PDF
Supplementary Figure Legends from Probody Therapeutic Design of 89Zr-CX-072 Promotes Accumulation in PD-L1–Expressing Tumors Compared to Normal Murine Lymphoid Tissue
2023 · Danique Giesen, Linda N. Broer, et al.
Figure S6 from Probody Therapeutic Design of 89Zr-CX-072 Promotes Accumulation in PD-L1–Expressing Tumors Compared to Normal Murine Lymphoid Tissue
2023 · Danique Giesen, Linda N. Broer, et al.
Works count: 39
Citation count: 956
H-index: 13
I10-index: 15
Year
Topic
Type